{
"info": {
"nct_id": "NCT02000531",
"official_title": "Ensure Extension Study to Assess the PFS of First-Line Erlotinib (Tarceva®) and Erlotinib After the Time of Disease Progression in Chinese Population Enrolled in the Ensure Trial",
"inclusion_criteria": "* Participant in ENSURE trial\n* Disease progression during first-line treatment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* N/A",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Participant in ENSURE trial",
"criterions": [
{
"exact_snippets": "Participant in ENSURE trial",
"criterion": "ENSURE trial participation",
"requirements": [
{
"requirement_type": "participation",
"expected_value": true
}
]
}
]
},
{
"line": "* Disease progression during first-line treatment",
"criterions": [
{
"exact_snippets": "Disease progression during first-line treatment",
"criterion": "disease progression",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "during first-line treatment"
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [
{
"line": "* N/A",
"criterions": []
}
],
"failed_miscellaneous": []
}